Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare effects of erlotinib and pemetrexed as maintenance
therapy for lung adenocarcinoma. Primary Outcome is the progression free survival (PFS).
Based on prediction of different potential benefit groups, this study may help the oncologist
to optimize and improve the maintenance therapy plan for lung adenocarcinoma.